Metabolomic Exploration of Dysregulated Lipid Metabolism in MFN2-related CMT2A (MetaDLM_CMT2A)

Charcot-Marie-Tooth Disease Type 2A Clinical Trial

Official title:

Metabolomic Exploration of Dysregulated Lipid Metabolism in MFN2-related CMT2A (CMT2A) Linked to Mitofusin 2

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04881201
• Other study ID #: 2021-A00834-34
• Status: Recruiting
• Phase: N/A
• Start date: January 5, 2022
• Est. completion date: July 5, 2024

Study information

• Verified date: September 2023
• Source: University Hospital, Angers
• Contact: Julien Cassereau, MD
• Phone: 0033 2 41 35 79 33
• Email: JuCassereau[@]chu-angers.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Charcot-Marie-Tooth (CMT) disease is the commonest sensitivo-motor inherited peripheral neuropathies with a prevalence of about 10-30 per 100,000. To date, more than 80 genes have been found responsible for CMT. Some of these genes code for mitochondrial proteins such as mitofusin 2 (MFN2).

In the last few years, our laboratory has developed strong expertise in metabolomics. The MetaDLM_CMT2A project proposes to produce metabolomic and lipidomic maps in CMT2A plasma from a cohort of genetically and clinically characterized patients with a national recruitment.

In the perspective of future clinical trials, these biomarkers and the better understanding of lipid metabolism defects in CMT2A would be of major interest in monitoring the evolution of the disease and developing specific therapeutic approaches.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: July 5, 2024
• Est. primary completion date: July 5, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

For all participants :

• Adult person

• Person on an empty stomach at the time of inclusion

• Person who signed the study participation consent form

• Person affiliated or beneficiary of a social security scheme

Patients Charcot-Marie-Tooth :

• Patient with symptoms of Charcot-Marie-Tooth disease on clinical examination clinical examination

• Patient with axonal neuropathy confirmed by an electrophysiological study electrophysiological study with a median nerve conduction velocity > 38 m / s

• Patient with documented pathogenic mutation (class 4 or class 5) in the MFN2 or patient with a variant of uncertain significance, as determined by the laboratory performing the test, if the variant of unknown significance has been found in found in multiple affected individuals in a family and not found in unaffected family members in unaffected family members.

Control subject :

• Each control is matched in age and sex to a case previously included in the study.

Exclusion Criteria:

For all participants :

• Pregnant, breastfeeding or parturient woman

• Person deprived of liberty by judicial or administrative decision

• Person subject to forced psychiatric care

• Person subject to a legal protection measure

• Person unable to give consent

Patients Charcot-Marie-Tooth :

• Patient with a neuropathy other than CMT2A (such as diabetic neuropathy or any other cause of acquired neuropathy) neuropathy or any other cause of acquired neuropathy), medical history of kidney stones kidney stones or cardiovascular risk factors (dyslipidaemia diabetes, severe obesity (BMI >35 kg/m²))

• Patient treated with Idebenone at the time of inclusion. (It is possible to include a patient treated with Idebenone if the treatment was interrupted at least 5 days before)

Control subject :

• Person with neuropathy, medical history of kidney stones or cardiovascular risk factors cardiovascular risk factors (dyslipidaemia, diabetes, severe obesity (BMI >35 kg/m²))

Related Conditions & MeSH terms

• Charcot-Marie-Tooth Disease
• Charcot-Marie-Tooth Disease Type 2A
• Hereditary Sensory and Motor Neuropathy
• Nerve Compression Syndromes
• Tooth Diseases

Intervention

Procedure:
• blood sample
blood sample

Locations

Country	Name	City	State
France	CHU	Angers	Maine Et Loire

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare the metabolomics and lipidomics of CMT2A patients compared to witnesses using high resolution mass spectrometry	We will compare the metabolomics and lipidomics of CMT2A patients compared to controls using high resolution mass spectrometry, by comparing the presence or not of the metabolites sought thanks to thetechnology developed by the company Biocrates (MxP-Quant-500 kit), allowing testing of 630 polar and lipid metabolites, under conditions close to medical biology.	at enrollment